ABCD： Adiposity-based Chronic Disease：肥満は慢性疾患として対応すべき

肥満は慢性疾患として対応すべき

良質なリソース・エビデンスを含むガイドラインとなっているとのこと

特定の食品を推奨するようなものでもなく、単なるカロリー量を絞ることを推奨しているわけでもない



American Association of Clinical Endocrinologists と American College of Endocrinologyからposition statementの“posiiton statement”報告

ABCD： Adiposity-based Chronic Disease


AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
W. Timothy Garvey, et. al.
ENDOCRINE PRACTICE Vol 22 (Suppl 3) July 2016 1
http://journals.aace.com/doi/pdf/10.4158/EP161365.GL



このパラダイム骨幹概念はすでに出版済み

Advanced Framework for a New Diagnosis of Obesity as a Chronic Disease
https://www.aace.com/files/2014-advanced-framework-for-a-new-diagnosis-of-obesity-as-a-chronic-disease.pdf 

2014 Consensus Conference on Obesity
AACE/ACE Guidelines AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY
COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR
MEDICAL CARE OF PATIENTS WITH OBESITY
http://journals.aace.com/doi/pdf/10.4158/EP161365.GL?code=aace-site

---

改めてだが・・・
日本のウェスト径基準は、WHOのアジア人基準に比べても乖離甚だしい

Q6. Is lifestyle/behavioral therapy effective to treat overweight and obesity, and what components of lifestyle therapy are associated with efficacy?

• R64. A structured lifestyle intervention program designed for weight loss (lifestyle therapy) and consisting of a healthy meal plan, physical activity, and behavioral interventions should be available to patients who are being treated for overweight or obesity (Grade A; BEL 1).

Q6.1. Reduced-calorie meal plan and macronutrient composition.
• R65. Reducing total energy (caloric) intake should be the main component of any weight-loss intervention (Grade A; BEL 1)

• R66. Even though the macronutrient composition of meals has less impact on weight loss than adherence rates in most patients, in certain patient populations, modifying macronutrient composition may be considered to optimize adherence, eating patterns, weight loss, metabolic profiles, risk factor reduction, and and/or clinical outcomes (Grade A; BEL 1)